Testing a new drug combo for advanced bile duct cancer
Part of Cancer clinical trials.
This trial tests a combination of three medicines—an immunotherapy (sintilimab), an anti-angiogenic drug (bevacizumab), and two chemotherapy drugs (gemcitabine and cisplatin, called AG)—as a first treatment for bile duct cancer that cannot be removed by surgery. The goal is to see if this cocktail can shrink tumors or slow their growth better than standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of bile duct cancer that cannot be removed by surgery and has spread or is advanced.
- You must not have had any previous drug treatment for your cancer, or if you had it after surgery, it must have ended more than 6 months ago.
- Your daily activities should be mostly unaffected (able to do light work or fully active).
- Your blood counts, liver, and kidney function must be within a certain range (your doctor will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of cancer medicines (gemcitabine plus albumin-paclitaxel) along with immune therapy (sintilimab) and a blood-vessel–targeting drug (bevacizumab). It’s for people with gallbladder cancer that can’t be removed by surgery, to see if the treatment controls the cancer and improves outcomes.
This Phase 2 trial tests a combination of three medicines (GEMOX, donafenib, and tislelizumab) for advanced bile duct cancer. It aims to see if the treatment can shrink tumors and improve outcomes in people with certain tumor stage and health test results.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This trial tests whether giving a drug that blocks blood vessel growth (anti-angiogenic therapy) after immunotherapy can help people with advanced bile duct, gallbladder, or cholangiocarcinoma that cannot be removed by surgery. The goal is to see if this sequence improves outcomes for patients who have not had prior treatment for advanced disease.
This trial tests whether combining chemotherapy, radiation, and an immunotherapy drug (sintilimab) can help people with intrahepatic bile duct cancer that hasn't been treated before. It aims to see if this triple approach is safe and effective.
Hear when a new ORR,OS,PFS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.